FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023483135> ?p ?o ?g. }

• W2023483135 endingPage "662" @default.
• W2023483135 startingPage "649" @default.
• W2023483135 abstract "BACKGROUND: Acute β-blockade has been associated with a dose-dependent increase in adverse outcomes, including stroke and mortality. Acute blood loss contributes to the incidence of these adverse events. In an attempt to link the risks of acute blood loss and β-blockade, animal studies have demonstrated that acute β-blockade impairs cerebral perfusion after hemodilution. We expanded on these findings by testing the hypothesis that acute β-blockade with a highly β1-specific antagonist (nebivolol) causes dose-dependent cerebral hypoxia during hemodilution. METHODS: Anesthetized rats and mice were randomized to receive vehicle or nebivolol (1.25 or 2.5 mg/kg) IV before hemodilution to a hemoglobin concentration near 60 g/L. Drug levels, heart rate (HR), cardiac output (CO), regional cerebral blood flow (rCBF, laser Doppler), and microvascular brain PO2 (PBrO2, G2 Oxyphor) were measured before and after hemodilution. Endothelial nitric oxide synthase (NOS), neuronal NOS (nNOS), inducible NOS, and hypoxia inducible factor (HIF)-1α were assessed by Western blot. HIF-α expression was also assessed using an HIF-(ODD)-luciferase mouse model. Data were analyzed using analysis of variance with significance assigned at P < 0.05, and corrected P values are reported for all post hoc analyses. RESULTS: Nebivolol treatment resulted in dose-specific plasma drug levels. In vehicle-treated rats, hemodilution increased CO and rCBF (P < 0.010) whereas PBrO2 decreased to 45.8 ± 18.7 mm Hg (corrected P < 0.001; 95% CI 29.4–69.7). Both nebivolol doses comparably reduced HR and attenuated the CO response to hemodilution (P < 0.012). Low-dose nebivolol did not impair rCBF or further reduce PBrO2 after hemodilution. High-dose nebivolol attenuated the rCBF response to hemodilution and caused a further reduction in PBrO2 to 28.4 ± 9.6 mm Hg (corrected P = 0.019; 95% CI 17.4–42.7). Both nebivolol doses increased brain endothelial NOS protein levels. Brain HIF-1α, inducible NOS, and nNOS protein levels and brain HIF-luciferase activity were increased in the high-dose nebivolol group after hemodilution (P < 0.032). CONCLUSIONS: Our data demonstrate that nebivolol resulted in a dose-dependent decrease in cerebral oxygen delivery after hemodilution as reflected by a decrease in brain tissue PO2 and an increase in hypoxic protein responses (HIF-1α and nNOS). Low-dose nebivolol treatment did not result in worsened tissue hypoxia after hemodilution, despite comparable effects on HR and CO. These data support the hypothesis that acute β-blockade with a highly β1-specific antagonist causes a dose-dependent impairment in cerebral perfusion during hemodilution." @default.
• W2023483135 created "2016-06-24" @default.
• W2023483135 creator A5001074686 @default.
• W2023483135 creator A5006536661 @default.
• W2023483135 creator A5006807707 @default.
• W2023483135 creator A5026371597 @default.
• W2023483135 creator A5033475698 @default.
• W2023483135 creator A5037021714 @default.
• W2023483135 creator A5041840962 @default.
• W2023483135 creator A5055456256 @default.
• W2023483135 creator A5076616582 @default.
• W2023483135 creator A5085298570 @default.
• W2023483135 creator A5085764571 @default.
• W2023483135 date "2013-03-01" @default.
• W2023483135 modified "2023-10-14" @default.
• W2023483135 title "Treatment with a Highly Selective β1 Antagonist Causes Dose-Dependent Impairment of Cerebral Perfusion After Hemodilution in Rats" @default.
• W2023483135 cites W1583443701 @default.
• W2023483135 cites W1830795510 @default.
• W2023483135 cites W1963649452 @default.
• W2023483135 cites W1967993059 @default.
• W2023483135 cites W1976788315 @default.
• W2023483135 cites W1978061068 @default.
• W2023483135 cites W1996022954 @default.
• W2023483135 cites W2004349360 @default.
• W2023483135 cites W2004899196 @default.
• W2023483135 cites W2007742842 @default.
• W2023483135 cites W2016162439 @default.
• W2023483135 cites W2018008610 @default.
• W2023483135 cites W2022004676 @default.
• W2023483135 cites W2025232088 @default.
• W2023483135 cites W2037505306 @default.
• W2023483135 cites W2048077518 @default.
• W2023483135 cites W2052357744 @default.
• W2023483135 cites W2054801761 @default.
• W2023483135 cites W2060172358 @default.
• W2023483135 cites W2081173561 @default.
• W2023483135 cites W2081325363 @default.
• W2023483135 cites W2108765715 @default.
• W2023483135 cites W2108897190 @default.
• W2023483135 cites W2122470811 @default.
• W2023483135 cites W2122659928 @default.
• W2023483135 cites W2122868264 @default.
• W2023483135 cites W2127075854 @default.
• W2023483135 cites W2127963725 @default.
• W2023483135 cites W2138392454 @default.
• W2023483135 cites W2138580984 @default.
• W2023483135 cites W2142838862 @default.
• W2023483135 cites W2143398582 @default.
• W2023483135 cites W2148194696 @default.
• W2023483135 cites W2160750115 @default.
• W2023483135 cites W2170858474 @default.
• W2023483135 doi "https://doi.org/10.1213/ane.0b013e318280e26d" @default.
• W2023483135 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23400988" @default.
• W2023483135 hasPublicationYear "2013" @default.
• W2023483135 type Work @default.
• W2023483135 sameAs 2023483135 @default.
• W2023483135 citedByCount "29" @default.
• W2023483135 countsByYear W20234831352013 @default.
• W2023483135 countsByYear W20234831352014 @default.
• W2023483135 countsByYear W20234831352015 @default.
• W2023483135 countsByYear W20234831352016 @default.
• W2023483135 countsByYear W20234831352017 @default.
• W2023483135 countsByYear W20234831352018 @default.
• W2023483135 countsByYear W20234831352020 @default.
• W2023483135 countsByYear W20234831352023 @default.
• W2023483135 crossrefType "journal-article" @default.
• W2023483135 hasAuthorship W2023483135A5001074686 @default.
• W2023483135 hasAuthorship W2023483135A5006536661 @default.
• W2023483135 hasAuthorship W2023483135A5006807707 @default.
• W2023483135 hasAuthorship W2023483135A5026371597 @default.
• W2023483135 hasAuthorship W2023483135A5033475698 @default.
• W2023483135 hasAuthorship W2023483135A5037021714 @default.
• W2023483135 hasAuthorship W2023483135A5041840962 @default.
• W2023483135 hasAuthorship W2023483135A5055456256 @default.
• W2023483135 hasAuthorship W2023483135A5076616582 @default.
• W2023483135 hasAuthorship W2023483135A5085298570 @default.
• W2023483135 hasAuthorship W2023483135A5085764571 @default.
• W2023483135 hasBestOaLocation W20234831351 @default.
• W2023483135 hasConcept C126322002 @default.
• W2023483135 hasConcept C146957229 @default.
• W2023483135 hasConcept C157767197 @default.
• W2023483135 hasConcept C164705383 @default.
• W2023483135 hasConcept C170493617 @default.
• W2023483135 hasConcept C178790620 @default.
• W2023483135 hasConcept C178853913 @default.
• W2023483135 hasConcept C185592680 @default.
• W2023483135 hasConcept C197934379 @default.
• W2023483135 hasConcept C2777537511 @default.
• W2023483135 hasConcept C2777622882 @default.
• W2023483135 hasConcept C2778468042 @default.
• W2023483135 hasConcept C42219234 @default.
• W2023483135 hasConcept C519581460 @default.
• W2023483135 hasConcept C540031477 @default.
• W2023483135 hasConcept C71924100 @default.
• W2023483135 hasConcept C7836513 @default.
• W2023483135 hasConcept C84393581 @default.
• W2023483135 hasConcept C98274493 @default.
• W2023483135 hasConceptScore W2023483135C126322002 @default.

• next